2Miquel JF,Gilbert J.A chemical classification of nonsteroidal antagonists of sex-steroid hormone action.J Steroid Biochem,1988,31(4B):525 ～544
3Dowsett M,Bundred NJ,Decensi A,et al.Effect of raloxifene on breast cancer cell Ki67 and apoptosis:a double-blind,placebo -controlled,randomized clinical trial in postmenopausal patients.Cancer Epidemiol Biomarkers Prey,2001,10:961 ～966
4Bowie ML,Dietze EC,Delrow J,et al.Interferon-regulatory factor -1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells.Oncogene,2004,23:8743 ～ 8755
5Kennel P,Pallen C,Barale-Thoms E,et al.Tamoxifen:28 -day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects.Arch Toxicol,2003,77 (9):487 ～499
6Bergman L,Beelen ML,Gallee MP,et al.Risk and prognosis of endometrial cancer after tamoxifen for breast cancer.Comprehensive Cancer Centres'ALERT Group.Assessment of Liver and Endometrial cancer Risk following Tamoxifen.Lacet,2000,356 (9233):881～887
7Ellmen J,Hakulinenp P,Partanen A,et al.Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.Breast Cancer Res Treat,2003,82 (2):103 ～111
8CuzickJ,Powles T,Ueronesi U,et al.Overview of the main outcomes in breast-cancer prevention trials.Lancet,2003,361 (9354):296～300
9Fisher B,Costantino JP,Wickerham DL,et al.Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst,1998,90 (18):1371～ 1388
10Kristensen B,Ejlertsen B,Mouridsen HT,et al.Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen.Breast Cancer Res Treat,1996,39 (3):321 ～326
二级参考文献123
1Riggs B L,Hartmann L C.Selective estrogen-receptor modulators--mechanisms of action and application to clinical practice[J].N Engl J Med,2003,348(7):618-629.
2Bouhoute A,Leclercq G E.Derivatives bearing the side-chain of tamoxifen antagonize the association between the estrogen receptor and calmodulin[J].Biochem Pharmacol,1994,47(4):748-751.
3Brzozowski A M,Pike A C W,Dauter Z,et al.Molecular basis of agonism and antagonism in the estrogen receptor[J].Nature (London) ,1997,389(6652): 753-758.
4Shiau A K,Barstad D,Loria P M,et al.The structural basis of oestrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J].Cell,1998,95(7): 927-937.
5Miller C P,Collini M D,Tran B D,et al.Design,synthesis,and preclinical characterization of novel,highly selective indole estrogens[J].J Med Chem,2001,44(11): 1654-1657.
6Suh N,Glasebrook A L,Palkowitz A D,et al.Arzoxifene,a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer[J].Cancer Res,2001,61(23): 8412-8415.
7Schafer J M,Liu H,Bentrem D J,et al.Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351[J].Cancer Res,2000,60(18):5097-5105.
8Grese T A,Sluka J P,Bryant H U,et al.Molecular determinants of tissue selectivity in estrogen receptor modulators[J].Proc Natl Acad Sci U S A,1997,94(25):14105-14110.
9Dodge J A,Lugar C W,Cho S,et al.Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity[J].J Steroid Biochem Mol Biol,1997,61(1-2):97-106.
10Jordan V C.Antiestrogens and selective estrogen receptor modulators as multifunctional medicines.2.clinical considerations and new agents[J].J Med Chem,2003,46(7):1081-1111.
